Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Keeping Track: US FDA's Late Summer Approval Extravaganza Stars Three Novel Agents, Features Return Of Mylotarg

Executive Summary

Kymriah, Vabomere, and benzidazole approvals joined by new indications for Austedo, Faslodex.

Advertisement

Related Content

Actemra CAR-T-Related Indication Comes With Help From Novartis, Kite, US FDA
Cornering The Market On Innovation? The First CAR-T And The First Gene Therapy
Novartis Beats CAR-T Competitors To The Pricing Punch With Kymriah Approval
Novartis Begins CAR-T Payment Experiments With Outcomes-Based Contract With CMS
Novartis CAR-T Therapy's Swift Approval Aided By REMS And New US FDA Review Model
US Approvals Roundup: Cyltezo Biosimilar, Victoza CV Benefit, Gocovri In PD, Kedrab Rabies Biologic, Gout Combo Duzallo
Keeping Track: Oncology Stays Hot With Besponsa And Lynparza Approvals; New Uses Of Adcetris, Cabometyx Submitted
Mylotarg, Event-Free Survival Endpoint Both Get FDA Panel Endorsement
Help Wanted: FDA Recruiting New CBER Director Ahead Of Gene, Cell Therapy Wave
Pfizer Pulls Mylotarg For Safety 10 Years After Accelerated Approval

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

PS121441

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel